Bonjour à tous,
Vous trouverez ci-dessous les titres des publications des membres du réseau ENDOCAN TUTHYREF.
Félicitations aux auteurs!
Retrouvez les publications dans :
Janvier 2026
- André E, Mebarki L, Ilie M, Subtil F, Bournaud C, Borson-Chazot F, Descotes F, Lifante JC, Bertholon-Grégoire M, Lasolle H, Decaussin-Petrucci M. Validating the 2022 WHO classification in thyroid carcinomas: Prospective evidence for predicting iodine resistance. Histopathology. 2026 Mar 28. doi: 10.1111/his.70148. Epub ahead of print. PMID: 41902450.
Voir fichier : Andre2026-Validating-the-2022.pdf - Anizan N, Pignard A, Borget I, Lamartina L, Schlumberger M, Broggio D, Leboulleux S, Lamart S. Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine. Phys Med. 2026 May;145:105769. doi: 10.1016/j.ejmp.2026.105769. Epub 2026 Mar 19. PMID: 41861727.
Voir fichier : Anizan2026-Lesional-dosimetry.pdf - Ben Hamou A, Marchand JG, Poiree S, Ghander C, Buffet C, Russ G. Predictors of retreatment after radiofrequency ablation of benign thyroid nodules: role of pre-treatment growth rate and viable volume. Eur Thyroid J. 2026 Feb 25;15(1):ETJ250254. doi: 10.1530/ETJ-25-0254. PMID: 41697943.
Voir fichier : Ben-Hamou2026-Predictors.pdf - Bondet de La Bernardie S, Bernier MO, Buffet C, Lussey-Lepoutre C, Baudin C. Salivary and Lacrimal Disorders in Patients Treated with Radioiodine for Differentiated Thyroid Cancer: Systematic Review and Meta-Analyses. Eur Thyroid J. 2026 Apr 22:ETJ-25-0402. doi: 10.1530/ETJ-25-0402. Epub ahead of print. PMID: 42018484.
Voir fichier : Bondet-de-La-Bernardie2026-Salivary.pdf - Daclin S, Russ G, Poiree S, Marchand JG, Ghander C, Roy M, Menegaux F, Gaujoux S, Chereau N, Deniziaut G, Bigorgne C, Buffet C, Ben Hamou A. Enhancing patient selection for thyroid thermal ablation: insights from a multidisciplinary team approach. Int J Hyperthermia. 2026 Dec;43(1):2634738. doi: 10.1080/02656736.2026.2634738. Epub 2026 Mar 9. PMID: 41797561.
Voir fichier : Daclin2026-Enhancing-patient-selection.pdf - Decaussin-Petrucci M. Cas clinique n 7 : carcinome anaplasique de la thyroïde. Selon le système de Bethesda 2023 : malin (catégorie VI) [Case No. 7: Anaplastic thyroid carcinoma. According to the 2023 Bethesda system: Malignant (category VI)]. Ann Pathol. 2026 Jan 12:S0242-6498(25)00253-6. French. doi: 10.1016/j.annpat.2025.12.012. Epub ahead of print. PMID: 41530002.
Voir fichier : Decaussin-Petrucci2026-cas-clinique7.pdf - Decaussin-Petrucci M. Cas n 8. Métastase thyroïdienne d’un adénocarcinome colique. Selon le système de Bethesda 2023 : malin (catégorie VI) [Case #8. Thyroid metastasis of a colonic adenocarcinoma. According to the 2023 Bethesda system: Malignant (category VI)]. Ann Pathol. 2026 Apr 15:S0242-6498(26)00061-1. French. doi: 10.1016/j.annpat.2026.03.005. Epub ahead of print. PMID: 41991366.
Voir fichier : Decaussin-Petrucci2026-cas8.pdf - Fenniche S, Oukabli M, Oubaddou Y, Mohamed A, Elochi MR, Alghuzlan A, Laraqui A, Dakka N, Bakri Y, Dupuy C, El Hassani RA. CHD4 and NOX4 expression in thyroid tumor tissues. Explor Target Antitumor Ther. 2026 Mar 25;7:1002363. doi: 10.37349/etat.2026.1002363. PMID: 41908702; PMCID: PMC13022763.
Voir fichier: Fenniche-CHD4-and-NOX4.pdf - Hadoux J, Hernando J, Wong KH, Do Cao C, Lasolle H, Buffet C, Benisvy D, Illouz F, Schneegans O, Varnier R, Drui D, Zanetta S, Hescot S, Muller M, Nascimento C, Roudaut N, Khanal M, Zheng S, Li X, Singh R, Tian W, Afonso AS, Houot B, Borget I, Segall G. Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET. ESMO Open. 2026 Mar;11(3):106083. doi: 10.1016/j.esmoop.2026.106083. Epub 2026 Mar 3. PMID: 41780123; PMCID: PMC12969821.
Voir fichier: Hadoux2026-Real-world-external.pdf - Haissaguerre M, Schubert L, Lamartina L, Buffet C, Caron P. 2025 ATA Guidelines on well-differentiated thyroid cancer: How will they change our practice? Ann Endocrinol (Paris). 2026 Jan 8;87(2):102482. doi: 10.1016/j.ando.2026.102482. Epub ahead of print. PMID: 41519258.
Voir fichier: Haissaguerre2026-2025-ATA-Guidelines.pdf - Loreto-Palacio P, Decaussin-Petrucci M, Wilhelm S, Asa SL. Parathyroid Carcinoma Mimicking Thyroid Hyalinizing Trabecular Tumor: A Case Report and Review of Atypical Presentations of Parathyroid Carcinoma. Int J Surg Pathol. 2026 Mar 13:10668969261422690. doi: 10.1177/10668969261422690. Epub ahead of print. PMID: 41823014.
Voir fichier : Loreto-Palacio2026- Parathyroid-Carcinoma.pdf - Martinod E, Kuczma P, Trésallet C, Ghander C, Buffet C, Vicaut E. Rationale for using lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion. Eur Thyroid J. 2025 Dec 24;14(6):e250337. doi: 10.1530/ETJ-25-0337. PMID: 41734463; PMCID: PMC12742051.
Voir fichier : Martinod2026-Rationale-for-using.pdf - Mavromati M, Jarlborg P, Demarchi M, Leboulleux S. Refractory hypothyroidism: Diagnostic evaluation and management strategies. Ann Endocrinol (Paris). 2026 Feb;87(1):102489. doi: 10.1016/j.ando.2026.102489. Epub 2026 Feb 3. PMID: 41643853.
Voir fichier : Mavromati2026-Refractory.pdf - Mebarki L, Andre E, Subtil F, Bournaud C, Borson-Chazot F, Lifante JC, Abeillon J, Castellnou S, Descotes F, Raverot V, Bertholon-Gregoire M, Ilie MD, Decaussin-Petrucci M, Lasolle H. A histo-clinical score to predict evolution to radioactive iodine-refractory of the follicular cell-derived thyroid carcinoma (PREDIRAIR): a single-centre, prospective, cohort study. EClinicalMedicine. 2026 Mar 31;94:103839. doi: 10.1016/j.eclinm.2026.103839. PMID: 41969334; PMCID: PMC13068576.
Voir fichier : Mebarki2026-A-histo-clinical.pdf - Radom M, Buffet C, Cazarin J, Harinquet M, de Faria CC, Brayé F, Nobre C, Aglave M, Mesloub Y, Dayris T, Droin N, Godefroy K, Bani MA, Ghuzlan AA, Leboulleux S, Lamartina L, Dupuy C. NOX4-derived oxidative DNA damage impairs thyroid differentiation through an epigenetic mechanism in BRAF-mutated radioactive iodine refractory papillary thyroid cancer cells. Int J Biol Sci. 2026 Jan 15;22(4):1674-1692. doi: 10.7150/ijbs.123980. PMID: 41694580; PMCID: PMC12905579.
Voir fichier: Radom2026- NOX4-derived-oxidative.pdf - Schubert L, Caron P, Groussin L, Haissaguerre M. Update on key publications and guidelines on aggressive thyroid cancer in 2025. Ann Endocrinol (Paris). 2026 Jan 25;87(2):102483. doi: 10.1016/j.ando.2026.102483. Epub ahead of print. PMID: 41759403.
Voir fichier : Schubert2026-update.pdf - Trocchi P, Swart E, Aleshchenko E, Merzenich
H, Ronckers C, Baust K, Calaminus G, Langer T, Ihle P, Küpper-Nybelen J, Lüpkes C, Dröge P, Ruhnke T, Horenkamp-Sonntag D, Marschall U, Klein M, Spix C, Apfelbacher C, Gebauer J. Endocrine and metabolic late effects in childhood cancer survivors in Germany: the VersKiK study. Eur J Endocrinol. 2026 Feb 4;194(2):102-113. doi: 10.1093/ejendo/lvag010. Epub 2026 Jan 19. PMID: 41636640.
Voir fichier : Trocchi2026-Endocrine-and-metabolic.pdf
